New drug combo shows promise against tough blood cancer
NCT ID NCT01661881
First seen Apr 25, 2026 · Last updated Apr 25, 2026
Summary
This study tested a two-step drug combination (rituximab/bendamustine followed by rituximab/cytarabine) in 23 adults with newly diagnosed mantle cell lymphoma who were eligible for a stem cell transplant. The goal was to see if this approach could improve the number of patients achieving complete remission before transplant. While mantle cell lymphoma is not curable with standard therapy, this treatment aims to better control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02113, United States
Conditions
Explore the condition pages connected to this study.